147 related articles for article (PubMed ID: 9696289)
1. Different patterns of cell proliferation and death and oncogene expression in cutaneous malignant melanoma.
Miracco C; Santopietro R; Biagioli M; Lazzi S; Nyongo A; Vatti R; Luzi P
J Cutan Pathol; 1998 May; 25(5):244-51. PubMed ID: 9696289
[TBL] [Abstract][Full Text] [Related]
2. Apoptosis and proliferative activity of non-Hodgkin's lymphomas: comparison with expression of bcl-2, p53 and c-myc proteins.
Takano Y; Saegusa M; Ikenaga M; Okayasu I
Pathol Int; 1997; 47(2-3):90-4. PubMed ID: 9088026
[TBL] [Abstract][Full Text] [Related]
3. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
[TBL] [Abstract][Full Text] [Related]
4. Correlation of nuclear morphometry of primary melanoma of the skin with clinicopathological parameters and expression of tumor suppressor proteins (p53 and p16(INK4a)) and bcl-2 oncoprotein.
Mijovic Z; Kostov M; Mihailovic D; Zivkovic N; Stojanovic M; Zdravkovic M
J BUON; 2013; 18(2):471-6. PubMed ID: 23818364
[TBL] [Abstract][Full Text] [Related]
5. Major Histotypes in Skin Melanoma: Nodular and Acral Lentiginous Melanomas Are Poor Prognostic Factors for Relapse and Survival.
Tas F; Erturk K
Am J Dermatopathol; 2022 Nov; 44(11):799-805. PubMed ID: 35925149
[TBL] [Abstract][Full Text] [Related]
6. c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma.
Chana JS; Wilson GD; Cree IA; Alexander RA; Myatt N; Neale M; Foss AJ; Hungerford JL
Br J Ophthalmol; 1999 Jan; 83(1):110-4. PubMed ID: 10209447
[TBL] [Abstract][Full Text] [Related]
7. Neuropeptide Y expression in cutaneous melanoma.
Gilaberte Y; Roca MJ; Garcia-Prats MD; Coscojuela C; Arbues MD; Vera-Alvarez JJ
J Am Acad Dermatol; 2012 Jun; 66(6):e201-8. PubMed ID: 21620518
[TBL] [Abstract][Full Text] [Related]
8. Patterns of local horizontal spread of melanomas: consequences for surgery and histopathologic investigation.
Breuninger H; Schlagenhauff B; Stroebel W; Schaumburg-Lever G; Rassner G
Am J Surg Pathol; 1999 Dec; 23(12):1493-8. PubMed ID: 10584702
[TBL] [Abstract][Full Text] [Related]
9. Cell proliferation, bcl-2, c-myc, p53 and apoptosis as indicators of different aggressiveness in small lymphocytic lymphoma (SLL).
Palestro G; Ponti R; Chiusa L; Chiarle R; Geuna M; Novero D; Freilone R; Pich A
Eur J Haematol; 1997 Sep; 59(3):148-54. PubMed ID: 9310122
[TBL] [Abstract][Full Text] [Related]
10. Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium.
Ioffe OB; Papadimitriou JC; Drachenberg CB
Hum Pathol; 1998 Oct; 29(10):1150-9. PubMed ID: 9781657
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical and prognostic analysis of apoptosis and proliferation in uveal melanoma.
Mooy CM; Luyten GP; de Jong PT; Luider TM; Stijnen T; van de Ham F; van Vroonhoven CC; Bosman FT
Am J Pathol; 1995 Oct; 147(4):1097-104. PubMed ID: 7573354
[TBL] [Abstract][Full Text] [Related]
12. Expression of c-myc and bcl-2 in primary and advanced cutaneous melanoma.
Utikal J; Leiter U; Udart M; Kaskel P; Peter RU; Krähn GM
Cancer Invest; 2002; 20(7-8):914-21. PubMed ID: 12449722
[TBL] [Abstract][Full Text] [Related]
13. bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi.
Cerroni L; Soyer HP; Kerl H
Am J Dermatopathol; 1995 Feb; 17(1):7-11. PubMed ID: 7695015
[TBL] [Abstract][Full Text] [Related]
14. Differential clinical significance of alpha(v)Beta(3) expression in primary lesions of acral lentiginous melanoma and of other melanoma histotypes.
Kageshita T; Hamby CV; Hirai S; Kimura T; Ono T; Ferrone S
Int J Cancer; 2000 Mar; 89(2):153-9. PubMed ID: 10754493
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of proliferation- and apoptosis-related markers in lentigo maligna and solar keratosis keratinocytes.
Feinmesser M; Tsabari C; Fichman S; Hodak E; Sulkes J; Okon E
Am J Dermatopathol; 2003 Aug; 25(4):300-7. PubMed ID: 12876487
[TBL] [Abstract][Full Text] [Related]
16. Correlation of cell cycle regulatory proteins (p53 and p16(ink)⁴(a)) and bcl-2 oncoprotein with mitotic index and thickness of primary cutaneous malignant melanoma.
Kostov M; Mijović Z; Mihailović D; Cerović S; Stojanović M; Jelić M
Bosn J Basic Med Sci; 2010 Nov; 10(4):276-81. PubMed ID: 21108607
[TBL] [Abstract][Full Text] [Related]
17. "Triggered trap": nevoid malignant melanoma.
McNutt NS
Semin Diagn Pathol; 1998 Aug; 15(3):203-9. PubMed ID: 9711670
[TBL] [Abstract][Full Text] [Related]
18. C-fos protein expression in Spitz nevi, common melanocytic nevi, and malignant melanomas.
Bergman R; Kerner H; Manov L; Friedman-Birnbaum R
Am J Dermatopathol; 1998 Jun; 20(3):262-5. PubMed ID: 9650699
[TBL] [Abstract][Full Text] [Related]
19. Histological type and biological behavior of primary cutaneous malignant melanoma. 2. An analysis of 86 cases located on so-called acral regions as plantar, palmar, and sub-/parungual areas.
Søndergaard K
Virchows Arch A Pathol Anat Histopathol; 1983; 401(3):333-43. PubMed ID: 6415910
[TBL] [Abstract][Full Text] [Related]
20. Myc down-regulation sensitizes melanoma cells to radiotherapy by inhibiting MLH1 and MSH2 mismatch repair proteins.
Bucci B; D'Agnano I; Amendola D; Citti A; Raza GH; Miceli R; De Paula U; Marchese R; Albini S; Felsani A; Brunetti E; Vecchione A
Clin Cancer Res; 2005 Apr; 11(7):2756-67. PubMed ID: 15814658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
